Clinical Trial Detail

NCT ID NCT02311361
Title Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

pancreatic adenocarcinoma

Therapies

Durvalumab

Tremelimumab

Age Groups: adult

No variant requirements are available.